Patents by Inventor Shai Rubnov

Shai Rubnov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Random pentapolymer for treatment of autoimmune diseases
    Patent number: 9200114
    Abstract: The present invention relates to a synthetic polypeptide which is a random linear pentapolymer comprising alanine, glutamic acid, lysine, tyrosine and phenylalanine and use thereof in treating autoimmune diseases, in particular multiple sclerosis.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: December 1, 2015
    Assignee: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Shai Rubnov
  • Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium
    Patent number: 9102592
    Abstract: The present invention relates to processes for the preparation of quinoline-3-carboxamide derivatives, such as sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate (Laquinimod sodium). The present invention further relates to intermediates formed in such processes.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: August 11, 2015
    Assignee: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Michael Mizhiritskii, Shai Rubnov
  • Polymorphs of perampanel
    Patent number: 9096574
    Abstract: The present invention provides novel crystalline forms of perampanel, pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating seizures and epilepsy.
    Type: Grant
    Filed: January 1, 2013
    Date of Patent: August 4, 2015
    Assignee: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Shai Rubnov
  • Co-crystals of dapagliflozin
    Patent number: 9006188
    Abstract: The present invention provides novel co-crystal forms of dapagliflozin, namely a dapagliflozin lactose co-crystal and a dapagliflozin asparagine co-crystal, to pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating type 2 diabetes.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: April 14, 2015
    Assignee: Mapi Pharma Ltd.
    Inventors: Ehud Marom, Shai Rubnov
  • Intermediate compounds and process for the preparation of lurasidone and salts thereof
    Patent number: 8981095
    Abstract: The present invention relates to a process for the preparation of Lurasidone or a pharmaceutically acceptable salt thereof, a compound useful for the treatment of schizophrenia and bipolar disorder. The present invention further relates to processes for the preparation of Lurasidone intermediates, and to certain novel intermediates obtained by such processes.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: March 17, 2015
    Assignee: Mapi Pharma Ltd.
    Inventors: Ehud Marom, Michael Mizhiritskii, Susanna Tchilibon, Shai Rubnov
  • Process and intermediates for the preparation of abiraterone acetate
    Patent number: 8975244
    Abstract: The present invention relates to a process for the synthesis of (3beta)17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) represented by the structure of formula (1), and salts thereof, especially salts with pharmaceutically acceptable acids. The present invention further relates to certain intermediates in such processes.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: March 10, 2015
    Assignee: Mapi Pharma Ltd.
    Inventors: Ehud Marom, Shai Rubnov, Michael Mizhiritskii
  • INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM
    Publication number: 20150051419
    Abstract: The present invention relates to processes for the preparation of quinoline-3-carboxamide derivatives, such as sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate (Laquinimod sodium). The present invention further relates to intermediates formed in such processes.
    Type: Application
    Filed: August 28, 2014
    Publication date: February 19, 2015
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud MAROM, Michael MIZHIRITSKII, Shai RUBNOV
  • POLYMORPHS OF PERAMPANEL
    Publication number: 20140371273
    Abstract: The present invention provides novel crystalline forms of perampanel, pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating seizures and epilepsy.
    Type: Application
    Filed: January 1, 2013
    Publication date: December 18, 2014
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Shai Rubnov
  • AMORPHOUS FORM OF DOLUTEGRAVIR
    Publication number: 20140350004
    Abstract: The present invention provides an amorphous form of dolutegravir sodium, pharmaceutical compositions comprising same, methods for its preparation and use thereof as an antiretroviral agent.
    Type: Application
    Filed: September 2, 2012
    Publication date: November 27, 2014
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Shai Rubnov
  • CO-CRYSTALS OF DAPAGLIFLOZIN
    Publication number: 20140343010
    Abstract: The present invention provides novel co-crystal forms of dapagliflozin, namely a dapagliflozin lactose co-crystal and a dapagliflozin asparagine co-crystal, to pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating type 2 diabetes.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 20, 2014
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud MAROM, Shai RUBNOV
  • Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium
    Patent number: 8865742
    Abstract: The present invention relates to processes for the preparation of quinoline-3-carboxamide derivatives, such as sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate (Laquinimod sodium). The present invention further relates to intermediates formed in such processes.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: October 21, 2014
    Assignee: Mapi Pharma Ltd.
    Inventors: Ehud Marom, Michael Mizhiritskii, Shai Rubnov
  • Process for the preparation of alogliptin
    Patent number: 8841447
    Abstract: The present invention is based on the discovery of a process for preparing pyrimidin-dione compounds, especially alogliptin and its derivatives, which comprises the reaction of a urea derivative of formula (VIII) with a malonic acid or its derivatives to form intermediates of formulae (VII) or (VII-A), which are subsequently converted to a compound of formula (II) upon introduction of a leaving group X. Compound (II) then reacts with an amine to form compound (I), which is optionally converted to its salts of formula (IV).
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: September 23, 2014
    Assignee: Mapi Pharma Ltd.
    Inventors: Ehud Marom, Michael Mizhiritskii, Shai Rubnov
  • PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS
    Publication number: 20140228417
    Abstract: The present invention relates to processes and intermediates for the preparation of derivatives of 2-arylthiazole such as Febuxostat and its analogs. Febuxostat which is an inhibitor of xanthine oxidase, is used for the treatment of chronic hyperuricaemia in conditions in which urate deposition has occurred, such as gouty arthritis.
    Type: Application
    Filed: January 23, 2012
    Publication date: August 14, 2014
    Applicant: MAPI PHARMA LTD.
    Inventors: Michael Mizhiritskii, Ehud Marom, Shai Rubnov
  • Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
    Patent number: 8796226
    Abstract: Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the long acting pharmaceutical composition comprises a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: August 5, 2014
    Assignee: Mapi Pharma Ltd.
    Inventors: Ehud Marom, Shai Rubnov
  • Processes for the preparation of deferasirox, and deferasirox polymorphs
    Patent number: 8772503
    Abstract: The present invention relates to processes for the preparation of deferasirox, an oral iron chelator developed to treat iron overload due to e.g. multiple blood transfusions. The present invention further provides novel deferasirox pseudopolymorphs and a novel amorphous form of deferasirox, processes for their preparation, as well as pharmaceutical compositions comprising same, and use thereof in treating iron overload.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: July 8, 2014
    Assignee: Mapi Pharma Ltd.
    Inventors: Michael Mizhiritskii, Ehud Marom, Shai Rubnov
  • INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF
    Publication number: 20140179922
    Abstract: The present invention relates to a process for the preparation of Lurasidone or a pharmaceutically acceptable salt thereof, a compound useful for the treatment of schizophrenia and bipolar disorder. The present invention further relates to processes for the preparation of Lurasidone intermediates, and to certain novel intermediates obtained by such processes.
    Type: Application
    Filed: June 13, 2012
    Publication date: June 26, 2014
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Michael Mizhiritskii, Susanna Tchilibon, Shai Rubnov
  • PROCESS AND INTERMEDIATES FOR THE PREPARATION OF ABIRATERONE ACETATE
    Publication number: 20140155363
    Abstract: The present invention relates to a process for the synthesis of (3beta)17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) represented by the structure of formula (1), and salts thereof, especially salts with pharmaceutically acceptable acids. The present invention further relates to certain intermediates in such processes.
    Type: Application
    Filed: February 10, 2014
    Publication date: June 5, 2014
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud MAROM, Shai RUBNOV, Michael MIZHIRITSKII
  • Intermediate compounds and process for the preparation of fingolimod
    Patent number: 8735627
    Abstract: The present invention relates to processes for the preparation of (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (Fingolimod) and pharmaceutically acceptable salts thereof, and intermediates formed in such processes.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: May 27, 2014
    Assignee: Mapi Pharma Ltd.
    Inventors: Ehud Marom, Michael Mizhiritskii, Shai Rubnov
  • INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM
    Publication number: 20130245065
    Abstract: The present invention relates to processes for the preparation of quinoline-3-carboxamide derivatives, such as sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate (Laquinimod sodium). The present invention further relates to intermediates formed in such processes.
    Type: Application
    Filed: November 28, 2011
    Publication date: September 19, 2013
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Michael Mizhiritskii, Shai Rubnov
  • POLYMORPHS OF FEBUXOSTAT
    Publication number: 20130225830
    Abstract: The present invention provides new crystalline forms of febuxostat, pharmaceutical compositions comprising same, methods for their preparation and use thereof in treating hyperuricaemia.
    Type: Application
    Filed: March 17, 2011
    Publication date: August 29, 2013
    Applicant: MAPI PHARMA LIMITED
    Inventors: Ehud Marom, Shai Rubnov